Skip to main content
  • Report an Adverse Event
  • Locate an MSL
RNAiScience logo
Search Menu
  • Home
  • Alnylam & RNAi
  • Congresses & Publications
  • Therapeutic Areas
  • Our Therapies
  • Pipeline & Clinical Trials
  • Connect With Us
  • Payer Connect
  • Log in
  • Sign Up
Alnylam logo
  • Privacy Policy
  • |
  • Terms of Use
| © 2025 Alnylam

This site is intended for US healthcare professionals.
© 2025 Alnylam Pharmaceuticals, Inc. All rights reserved.
MED-US-ALL-2400001

RNAiScience logo
  • Home
  • Alnylam & RNAi
  • Congresses & Publications
  • Therapeutic Areas
  • Our Therapies
  • Pipeline & Clinical Trials
  • Connect With Us
  • Payer Connect
Alnylam logo
  • Privacy Policy
  • |
  • Terms of Use

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

  • Report an Adverse Event
  • Locate an MSL
  • Log in
|
  • Sign Up

Search Results for "amyloidosis"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited. 

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

  • AMVUTTRA® (vutrisiran)
  • GIVLAARI® (givosiran)
  • ONPATTRO® (patisiran)
  • OXLUMO® (lumasiran)

Meta-regression analysis of the association between change in six minute walk distance and survival in transthyretin-mediated amyloidosis with cardiomyopathy This link is a pdf
Bookmark this pageBookmark this page

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy This link is a pdf

Insights from the HELIOS-A Study This link is a pdf
Bookmark this pageBookmark this page

This deck highlights data from the Phase 3 HELIOS-A trial of vutrisiran in patients with hATTR-PN.

ATTR Management Guidelines This link is a pdf
Bookmark this pageBookmark this page

This deck highlights published guidelines on diagnosis, treatment and disease management of ATTR.

Musculoskeletal Manifestations Associated with ATTR Amyloidosis This link is a pdf
Bookmark this pageBookmark this page

This slide deck provides disease education on ATTR amyloidosis, focusing on the musculoskeletal manifestations associated with the disease and their importance for early diagnosis and patient care.

History of Polyneuropathy and Musculoskeletal Manifestations in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy in APOLLO-B This link is a pdf
Bookmark this pageBookmark this page

NfL as a Potential Biomarker in hATTR Amyloidosis This link is a pdf
Bookmark this pageBookmark this page

This slide deck presents an overview of neurofilament light chain (NfL) and data evaluating its use as a biomarker in hATTR amyloidosis, including data from the APOLLO, Global OLE, and HELIOS-A studies.

ATTR Amyloidosis Disease State Handout This link is a pdf
Bookmark this pageBookmark this page

This handout provides an overview of ATTR amyloidosis manifestations and the diagnostic tools that can be used to assess their presentation.

DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis This link is a pdf

Screening, Recognition, and Barriers to Diagnosis of ATTR This link is a pdf
Bookmark this pageBookmark this page

This deck highlights the screening, recognition, and barriers of diagnosis in ATTR.

Pagination

  • Previous page
  • 2 of 10
  • Next page

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.

This site is intended for US healthcare professionals.
© 2025 Alnylam Pharmaceuticals, Inc. All rights reserved.
MED-US-ALL-2400001

  • Privacy Policy
  • |
  • Terms of Use
| © 2025 Alnylam
Alnylam logo
RNAI Logo

You are now leaving this site and being directed to a third-party website that is not maintained by Alnylam. Alnylam does not endorse and is not responsible for content or maintenance of third-party websites.

ContinueCancel

RNAI Logo

You are now leaving this site and being directed to another Alnylam website.

ContinueCancel

RNAI Logo

Intended for US healthcare professionals. This site is intended to provide balanced, evidence-based information to support scientific exchange. It is not intended to provide medical advice or recommendations for clinical practice.

Information about investigational therapeutics or investigational uses of approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of FDA approval.

Alnylam does not recommend or suggest use of its products in any manner inconsistent with the approved Prescribing Information.

Are you a healthcare professional practicing in the United States?

I confirm I am a US healthcare professional

I am a US payer or healthcare decision maker

I am not a US healthcare professional, or a US payer or healthcare decision maker

I am an Alnylam Team Member

X
Don't miss out!

Sign in to bookmark information and create your personal library

Log in

Don't have an account? Sign up